About DnaJ homolog subfamily A member 1
DnaJ homolog subfamily A member 1 (DNAJA1) is a protein
from Homo sapiens identified by UniProt accession
P31689, 397 residues long.
MolForge cross-references it against 0 known binders and
149 disease associations.
Target properties
| Protein name | DnaJ homolog subfamily A member 1 |
| UniProt accession | P31689 |
| Gene | DNAJA1 |
| Organism | Homo sapiens |
| Length | 397 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (149)
Diseases linked to this target (Open Targets).
- reticulocyte count · score 0.20
- age at menopause · score 0.12
- reticulocyte measurement · score 0.11
- self reported educational attainment · score 0.11
- azoospermia · score 0.08
- cancer · score 0.07
- male infertility with teratozoospermia due to single gene mutation · score 0.06
- partial chromosome Y deletion · score 0.06
- urate measurement · score 0.05
- spermatogenic failure 63 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P31689-F1 | alphafold | PREDICTED | 83.26 | — |
Amino-acid sequence (397 residues)
MVKETTYYDV LGVKPNATQE ELKKAYRKLA LKYHPDKNPN EGEKFKQISQ AYEVLSDAKK RELYDKGGEQ AIKEGGAGGG FGSPMDIFDM FFGGGGRMQR ERRGKNVVHQ LSVTLEDLYN GATRKLALQK NVICDKCEGR GGKKGAVECC PNCRGTGMQI RIHQIGPGMV QQIQSVCMEC QGHGERISPK DRCKSCNGRK IVREKKILEV HIDKGMKDGQ KITFHGEGDQ EPGLEPGDII IVLDQKDHAV FTRRGEDLFM CMDIQLVEAL CGFQKPISTL DNRTIVITSH PGQIVKHGDI KCVLNEGMPI YRRPYEKGRL IIEFKVNFPE NGFLSPDKLS LLEKLLPERK EVEETDEMDQ VELVDFDPNQ ERRRHYNGEA YEDDEHHPRG GVQCQTS
Explore DnaJ homolog subfamily A member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets